Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

93.60USD
20 Nov 2017
Change (% chg)

$-0.01 (-0.01%)
Prev Close
$93.61
Open
$94.00
Day's High
$94.30
Day's Low
$92.89
Volume
1,113,196
Avg. Vol
1,624,882
52-wk High
$98.20
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

AbbVie, on conf call, says we need to see HCV market sort itself out
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc ::AbbVie CEO, on conf call, says we need to see HCV market sort itself out.AbbVie CEO, on conf call, says psoriasis business &, in general, areas where humira competes, has been and continues to be a relatively crowded market.AbbVie CEO, on conf call, says humira will still be a workhorse product within the psoriasis market, and risankizumab will fit in.AbbVie CEO, on conf call, says we would attempt to get a preliminary injunction to block any launches that violate our Humira IP ‍​.AbbVie, on conf call, says upadacitinib NDA next year will be filed with at least five of six studies ‍​.  Full Article

Abbvie reports Q3 adjusted earnings per share $1.41
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc ::Abbvie says Q3 earnings per share $1.01; Q3 adjusted earnings per share $1.41; Q3 net revenue $6,995 million versus $6,432 million.Abbvie says Q3 global humira net revenue $4.70 billion, up 15.8 percent on a reported basis.Q3 earnings per share view $1.38, revenue view $7.00 billion -- Thomson Reuters I/B/E/S.Abbvie says Q3 global imbruvica net revenue $688 million, up 37.3 percent on a reported basis.Abbvie says updates 2017 earnings per share guidance range to $4.27 to $4.29; raises 2017 adjusted earnings per share guidance range to $5.53 to $5.55.FY2017 earnings per share view $5.53 -- Thomson Reuters I/B/E/S.Abbvie says provides 2018 adjusted earnings per share guidance of $6.37 to $6.57.Fy2018 earnings per share view $6.56 -- Thomson Reuters I/B/E/S.Abbvie says on track to meet/exceed long-range guidance provided in Oct 2015; now expects 2020 global Humira sales to approach $21 billion.Announces a dividend increase of 11 percent, beginning with dividend payable in February 2018.2017 adjusted earnings per share outlook excludes $1.26 per share of intangible asset amortization expense, other items.  Full Article

Abbvie increases quarterly dividend by 11 percent
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc ::Abbvie increases quarterly dividend by 11 percent.Abbvie increases quarterly dividend by 11 percent.Sets quarterly cash dividend of $0.71 per share.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

AbbVie' Risankizumab meets all co-primary and ranked secondary endpoints
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Abbvie Inc :Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies.AbbVie - ‍Risankizumab safety profile consistent with that observed in phase 2 clinical trials, with no new safety signals detected across 3 studies​.AbbVie Inc - ‍In ultimma-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after last dose of study drug​.AbbVie Inc - ‍In ultimma-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after last dose of study drug​.AbbVie Inc - ‍In ultimma-1 and ultimma-2, serious adverse events through week 16 occurred in 2 percent of patients on risankizumab in both studies​.AbbVie Inc - ‍In ultimma-2, a second patient receiving risankizumab died 161 days after last dose, with cause of death unknown​.AbbVie - ‍In immvent, serious adverse events occurred in 3 percent of patients in risankizumab group and 3 percent of patients in adalimumab group by week 16​.AbbVie Inc - ‍continuing to evaluate potential of risankizumab across several immune-mediated conditions​.AbbVie Inc - in immvent​, ‍one adalimumab patient was diagnosed with stage iv gallbladder cancer and died three weeks after diagnosis during study.AbbVie -a patient treated with risankizumab died of acute myocardial infarction on immvent study day 73; had past history of cardiovascular risk factors​.  Full Article

AbbVie says ‍Health Canada approved inclusion of nail Psoriasis data in humira product monograph​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Abbvie Inc :AbbVie Inc says ‍Health Canada has approved inclusion of Nail Psoriasis data in Humira product monograph​.  Full Article

Alector and AbbVie announce collaboration
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - AbbVie Inc :Alector and AbbVie announce collaboration to advance a novel class of immune therapies for patients with Alzheimer's disease.AbbVie Inc - ‍Alector and AbbVie will co-fund development and commercialization and will share global profits equally​.AbbVie Inc - ‍Alector will receive a $205 million upfront payment and a potential, future equity investment of up to $20 million​.  Full Article

Cerveau Technologies signs agreement with AbbVie for Novel Tau imaging agent
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Cerveau Technologies Inc::Cerveau Technologies Inc signs license and supply agreement with AbbVie for Novel Tau imaging agent.Announced license and supply agreement with AbbVie for use of F-18MK-6240, an imaging agent to be used in PET scans​.  Full Article

Abbvie and harpoon therapeutics announce immuno-oncology research collaboration
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Abbvie Inc :Abbvie and Harpoon Therapeutics announce immuno-oncology research collaboration.Abbvie Inc - ‍financial terms were not disclosed.​.Abbvie Inc - ‍under terms of agreement, Harpoon will engineer tritac molecules directed against selected cancer targets using its proprietary platform​.Abbvie Inc says Harpoon will ‍provide Abbvie right to pursue further development and commercialization of the tritac molecules​.Abbvie - collaboration to incorporate Harpoon's tritac platform with co's research-stage immuno-oncology targets to develop novel cancer therapeutics​.  Full Article

AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - AbbVie Inc :AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology.AbbVie Inc - ‍AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral immunotherapies​.AbbVie Inc - ‍Abbvie has an option to obtain all global development and commercialization rights to Turnstone Biologics' Ad-MG1-MAGEA3 therapy​.AbbVie inc - ‍financial terms were not disclosed​.  Full Article

UPDATE 1-Novartis pitches new Cosentyx data as immunology crowd grows

* Cosentyx is now Novartis's No. 3 drug (Adds details about Cosentyx competition, comment from Novartis)